The objective of this study was to investigate the effects of autologous neurogenically induced bone marrow-derived mesenchymal stem cells (NIBM-MSCs) in two dogs suspected to have fibrocartilaginous embolic myelopathy (FCEM). Both dogs were paraplegic without deep pain perception (DPP) and tentatively diagnosed by MRI. Autologous NIBM-MSCs (5 × 106) were transplanted into the lumbar subarachnoid space two times with a 21-day interval for each patient. Based on a 21-month follow-up of the treated animals, the transplantation of NIBM-MSCs seems to be promising in subjects with FCEM lacking DPP.
Dog, subarachnoid transplantation, mesenchymal stem cells
CAN, PINAR; BEŞALTI, ÖMER; AKPINAR, EYLÜL; AKTAŞ, ZEYNEP; ELÇİN, AYŞE ESER; and ELÇİN, YAŞAR MURAT
"Subarachnoid transplantation of autologous neurogenically induced bone marrow derived mesenchymal stem cells for the treatment of fibrocartilaginous embolic myelopathy in two dogs,"
Turkish Journal of Veterinary & Animal Sciences: Vol. 40:
1, Article 19.
Available at: https://journals.tubitak.gov.tr/veterinary/vol40/iss1/19